Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and ...

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our ...

By Michael Erman and Julie Steenhuysen Aug 28 (Reuters) - Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant ...

Prior to the melanoma outcome, indicators included an enrolled trial, a partner covering half the expenses, and a market that ...

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares?

The companies have not published the trial data but said in a news release that the experimental treatment extended the time ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

The biotech firm announced plans to raise $2 billion through convertible notes, which could be increased to $2.3 billion.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the ...

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of ...